Navigation Links
NEJM Report Finds HPV Test More Effective Than Pap in Determining Cervical Cancer Risk
Date:10/18/2007

GAITHERSBURG, Maryland and HILDEN, Germany, October 18 /PRNewswire/ -- The first randomized, controlled study in North America of HPV testing as a stand-alone screen concluded that it is almost 40 percent more accurate than traditional cytology (the Pap "smear") in identifying women with advanced cervical disease, according to a report published today in The New England Journal of Medicine.

The study, which involved more than 10,000 Canadian women age 30-69, found that the HPV test's sensitivity - its ability to accurately identify women with pre-cancerous cervical cells or cancer - was 94.6 percent, compared to 55.4 percent for the Pap. HPV (humanpapilloma virus) is the primary cause of cervical cancer.

This seminal study used QAIGEN's Hybrid Capture(R) 2 High-Risk HPV DNA test -- the only such test that is both CE-marked in Europe and approved by the U.S. Food and Drug Administration(1). The molecular diagnostic test was developed by Digene Corp., now part of QIAGEN N.V. (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA). The performance of QIAGEN's HPV test has been validated in studies that included more than 300,000 women.

"We already knew before conducting this study that the sensitivity of the Pap left a lot to be desired," stated one of the study's authors, Eduardo Franco, DrPH, of Montreal's McGill University, in a news announcement. "However, 55.4 percent accuracy is only slightly above chance. Flipping a coin gives you 50 percent."

Participants in the Canadian Cervical Cancer Screening Trial (CCCaST) were randomly assigned to a "focus on Pap" or "focus on HPV" screening group, although for ethical reasons, both groups received both tests. In this study, conventional cytology was used. Recent analyses have found that the newer "liquid-based" cytology does not significantly improve the ability to detect disease. All CCCaST participants who tested positive on either the Pap or HPV test were referred for a follow-up biopsy. In addit
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. No harm in reducing prenatal check up to 3 - 6 times says WHO report
2. Autopsy reports could be valuable and informative
3. China reports declining number of SARS Cases
4. Russia Reports First SARS Case
5. Report on the Safety and Effectiveness of Melatonin supplements
6. WHO report asks for improved healthcare for mother and child
7. Research reports that c-section deliveries are rising
8. Jharkhand reports 13,000 Malaria cases
9. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
10. Experts Insist That Neonatal Herpes Be Reported Regularly
11. Uganda Reports Failure To Contain Sleeping Sickness
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 1DSS Research Announces Senior Health Risk Assessment 28SrHRA 29 28TM 29 58537 2Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 1Pan American Life Insurance Group Plans to Complete Coverage in Central America With Entry Into Costa Rica 3B Company Files Request for Authorization 58534 2Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 1Sport Science Lab Maintains That Injury to USC Football Player is Symptomatic of the Dangers of Conventional Weight Training 58530 2